vs
Side-by-side financial comparison of WEIBO Corp (WB) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.3B, roughly 1.9× WEIBO Corp). WEIBO Corp runs the higher net margin — 35.7% vs 25.3%, a 10.4% gap on every dollar of revenue. Over the past eight quarters, WEIBO Corp's revenue compounded faster (22.6% CAGR vs 4.4%).
Weibo Corporation is a Chinese social network company known for the microblogging website Sina Weibo. It is based in Beijing, China.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
WB vs ZTS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.4B |
| Net Profit | $458.3M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 29.1% | 31.9% |
| Net Margin | 35.7% | 25.3% |
| Revenue YoY | — | 3.0% |
| Net Profit YoY | — | 3.8% |
| EPS (diluted) | — | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.4B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $841.7M | $2.5B | ||
| Q1 25 | $396.9M | $2.2B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $833.4M | $2.4B | ||
| Q1 24 | $395.5M | $2.2B |
| Q4 25 | — | $603.0M | ||
| Q3 25 | $458.3M | $721.0M | ||
| Q2 25 | $234.8M | $718.0M | ||
| Q1 25 | $108.1M | $631.0M | ||
| Q4 24 | — | $581.0M | ||
| Q3 24 | $297.4M | $682.0M | ||
| Q2 24 | $164.6M | $624.0M | ||
| Q1 24 | $51.1M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | — | 31.9% | ||
| Q3 25 | 29.1% | 37.0% | ||
| Q2 25 | 30.4% | 36.7% | ||
| Q1 25 | 27.8% | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | 29.0% | 36.6% | ||
| Q2 24 | 28.2% | 33.0% | ||
| Q1 24 | 25.2% | 34.1% |
| Q4 25 | — | 25.3% | ||
| Q3 25 | 35.7% | 30.0% | ||
| Q2 25 | 27.9% | 29.2% | ||
| Q1 25 | 27.2% | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | 22.9% | 28.6% | ||
| Q2 24 | 19.8% | 26.4% | ||
| Q1 24 | 12.9% | 27.4% |
| Q4 25 | — | $1.37 | ||
| Q3 25 | — | $1.63 | ||
| Q2 25 | — | $1.61 | ||
| Q1 25 | — | $1.41 | ||
| Q4 24 | — | $1.29 | ||
| Q3 24 | — | $1.50 | ||
| Q2 24 | — | $1.37 | ||
| Q1 24 | — | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.9B | $3.3B |
| Total Assets | $6.9B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.2B | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | $1.9B | $1.6B | ||
| Q1 24 | $2.1B | $2.0B |
| Q4 25 | — | $3.3B | ||
| Q3 25 | $3.9B | $5.4B | ||
| Q2 25 | $3.6B | $5.0B | ||
| Q1 25 | $3.5B | $4.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | $3.4B | $5.0B | ||
| Q1 24 | $3.3B | $5.1B |
| Q4 25 | — | $15.5B | ||
| Q3 25 | $6.9B | $15.2B | ||
| Q2 25 | $6.5B | $14.5B | ||
| Q1 25 | $6.7B | $14.1B | ||
| Q4 24 | — | $14.2B | ||
| Q3 24 | — | $14.4B | ||
| Q2 24 | $7.1B | $14.2B | ||
| Q1 24 | $7.3B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $893.0M | ||
| Q3 25 | — | $938.0M | ||
| Q2 25 | — | $486.0M | ||
| Q1 25 | — | $587.0M | ||
| Q4 24 | — | $905.0M | ||
| Q3 24 | — | $951.0M | ||
| Q2 24 | — | $502.0M | ||
| Q1 24 | — | $595.0M |
| Q4 25 | — | $732.0M | ||
| Q3 25 | — | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $455.0M |
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
